In conclusion, our findings support IL-33 role in association with IL-13 in a subset of SSc patients with ILD and with the diffuse cutaneous form and warrant further longitudinal studies to assess the validity of these two interleukins as potential therapeutic targets and biomarkers for severe SSc-ILD. Here, IL33 is linked to systemic sclerosis.